LY 518674

Known as: LY-518674, LY518674 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
AIMS Fibrate medications weakly stimulate the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α) and are… Expand
  • table 1
  • figure 1
Is this relevant?
2009
2009
Expression of ATP binding cassette transporter A1 (ABCA1), a major regulator of high density lipoprotein (HDL) biogenesis, is… Expand
Is this relevant?
2009
2009
OBJECTIVE The study of PPAR-alpha activation on apoA-I production in humans has been limited to fibrates, relatively weak PPAR… Expand
Is this relevant?
2008
2008
Fibric acid-shaped drugs raise high-density lipoprotein (HDL) cholesterol by upregulating the HDL-related genes through… Expand
Is this relevant?
2008
2008
Objective—The study of PPARactivation on apoA-I production in humans has been limited to fibrates, relatively weak PPARagonists… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2007
2007
CONTEXT Fibrates are weak agonists of peroxisome proliferator-activated receptor alpha (PPAR-alpha). No trials have reported… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2005
2005
Low high-density lipoprotein-cholesterol (HDL-c) is an important risk factor of coronary artery disease (CAD). Optimum therapy… Expand
Is this relevant?
2005
2005
Low high-density lipoprotein-cholesterol (HDL-c) is an important risk factor of coronary artery disease (CAD). Optimum therapy… Expand
  • figure 2
  • table 1
  • figure 3
  • table 2
  • figure 4
Is this relevant?